Literature DB >> 35668318

Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.

Stergios A Polyzos1, Niki Katsiki2.   

Abstract

Entities:  

Keywords:  Cilofexor; Combination; Fibrosis; Firsocostat; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity; Semaglutide; Steatosis; Treatment

Mesh：

Substances：

Year:  2022        PMID： 35668318     DOI： 10.1007/s42000-022-00379-6

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN： 1109-3099            Impact factor:   3.419


× No keyword cloud information.
  2 in total

Review 1.  Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease.

Authors:  Tieshan Teng; Shuai Qiu; Yiming Zhao; Siyuan Zhao; Dequan Sun; Lingzhu Hou; Yihang Li; Ke Zhou; Xixi Yu; Changyong Yang; Yanzhang Li
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

2.  Note by Hormones' new editor: metabolic syndrome plus obesity and COVID-19, the two concurrent pandemics and the field of endocrinology.

Authors:  Constantine A Stratakis
Journal:  Hormones (Athens)       Date:  2022-09       Impact factor: 3.419
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.